GlyProVac ApS


GlyProVac is a biotech spinout from University of Southern Denmark. Using our BEMAP technology we develop novel vaccine candidates targeting bacterial infections with no current methods of prevention. Our antigens are unique in including highly immunogenic site-specific sugar modifications. GlyProVac’s first candidate targets E. coli with healthcare associated urinary tract infections as primary indication.